Vistra (VST) Form 144: 19,592 Shares ($3.93M) Proposed Sale
Vistra Corp. Form 144 notice shows a proposed sale of 19,592 common shares with an aggregate market value of $3,933,635.66, scheduled for 09/10/2025 through Fidelity Brokerage Services LLC on the NYSE.
Rhea-AI Filing Summary
Vistra Corp. Form 144 notice shows a proposed sale of 19,592 common shares with an aggregate market value of $3,933,635.66, scheduled for 09/10/2025 through Fidelity Brokerage Services LLC on the NYSE. The filing reports the securities were acquired by option grants dated 10/11/2016 (17,600 shares) and 04/06/2018 (1,992 shares), with payment recorded as cash on 09/10/2025. The registrant’s outstanding shares are listed as 338,820,324. The form states no securities were sold by the reporting person in the past three months. The filing lacks a populated issuer name and filer identification in the provided extract, which is not specified in the content.
Positive
- Sale scheduled through a major broker (Fidelity), indicating use of an established execution channel
Negative
- Extract lacks issuer name and filer identification, reducing traceability of the filing from the provided content
Insights
TL;DR: Routine Form 144: a small scheduled sale by option holders, executed through a major broker; limited market impact.
The notice documents a proposed sale of 19,592 common shares valued at $3.93 million to be executed on 09/10/2025 via Fidelity on the NYSE. Acquisition sources are option grants from 2016 and 2018, indicating these are vested option shares rather than recent purchases. The position represents a vanishingly small percentage of the listed 338.8 million outstanding shares, suggesting negligible dilution or market pressure. The filing is informational and follows Rule 144 protocols; it does not include the filer’s identifying CIK/CCC or a populated issuer name in the provided extract, which limits traceability.
TL;DR: Disclosure is consistent with Rule 144 but missing some identifying details in the extract, reducing transparency.
The form indicates compliance with Rule 144 reporting for a planned sale via an institutional broker and discloses acquisition via option grants, dates, and cash payment. This level of detail about grant dates (10/11/2016 and 04/06/2018) supports review of insider grant timing and vesting. However, the absence of an explicitly populated issuer name and filer identifiers in the provided content is a governance shortfall in this extract and should be resolved to ensure clear public disclosure and traceability of insider transactions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the aggregate market value and where will the sale be executed?
Was payment for the acquired securities made in cash?
Have any securities been sold by the reporting person in the past three months?
Are there any disclosure gaps in the provided Form 144 extract?
AI-generated analysis. How Rhea-AI works. Not financial advice.